Company Achieves Important Milestone in Development of Next Generation
CALGARY, June 5 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company dedicated to developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has demonstrated that its safflower-produced Apo AI(Milano) (safflower Apo AI(Milano)) is functional in a widely accepted animal model. Working with the laboratory of Dr. Jean Claude Tardif at the Montreal Heart Institute (MHI), the company demonstrated that safflower Apo AI(Milano) increased cholesterol mobilization substantially in mice which, in conjunction with analytical and in vitro assays, indicates that safflower Apo AI(Milano) is physiologically and pharmaceutically comparable to microbially-produced Apo AI. In human trials, microbially-produced Apo AI(Milano) has been demonstrated to remove plaque from arteries (plaque regression), and holds potential for addressing one of the greatest unmet medical needs today - the reversal of atherosclerosis.
Dr. Maurice Moloney, founder and chief scientific officer of SemBioSys commented, "Scientists at SemBioSys and our academic collaborators have conducted extensive work on safflower Apo AI(Milano) and have established that safflower Apo AI(Milano) is comparable to Apo AI derived from other sources, as described in the literature. Its identity and functionality was confirmed through use of mass spectrometry, and lipid clearance, cellular cholesterol efflux and whole-animal cholesterol mobilization assays."
Dr. Jean-Claude Tardif, director of the Montreal Heart Institute
Research Centre, who is a world leader in the study of HDLs and the
physiological role of Apo AI noted, "Apo AI and Apo AI(Milano) hold the
potential to be a useful therapy for the treatment of cardiovascular
disease through the unique mechanism of plaque regression. Our research at
|SOURCE SemBioSys Genetics Inc.|
Copyright©2008 PR Newswire.
All rights reserved